SUBSCRIBE
SUBSCRIBE

Phase I

Novartis to Hold On to Its 33% Stake in Roche—For Now
Drug Development
Spectacular Data Posted for Novartis AG’s Next Generation CAR-T Drug
May 31, 2017
 · 
3 min read
Drug Development
100-Year-Old Drug Extremely Promising For Treating Autism, University of San Diego Study
May 30, 2017
 · 
1 min read
3 Biotechs That Could be Taken Out This Quarter
Drug Development
5 Big Pharmas Facing Catalysts in 2017
May 25, 2017
 · 
3 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Drug Development
6 (Plus 2!) Most Notable ASCO Abstracts So Far
May 22, 2017
 · 
3 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Drug Development
5 Biotechs Releasing Highly-Anticipated Data at ASCO
May 19, 2017
 · 
2 min read
Drug Development
TG Therapeutics: Significant Near-Term Catalysts For 2017
May 16, 2017
 · 
1 min read
3 Biotechs That Could be Taken Out This Quarter
Drug Development
4 Biotechs That Could Release Stock-Shattering Data Soon
May 10, 2017
 · 
3 min read
Drug Development
4 Biotechs That Could Explode Or Crash In May
May 5, 2017
 · 
1 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
3 Cancer Biotechs to Watch at ASCO
May 5, 2017
 · 
2 min read
Secretive Moderna Shakes Up R&D Model, Shows Off Early-Stage Trial Data
Drug Development
Biotech Unicorn Moderna’s Vaccine Performs Well in First Human Trial
April 28, 2017
 · 
2 min read
Load More
PRESS RELEASES
Drug Development
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers
June 3, 2023
 · 
11 min read
Drug Development
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
June 3, 2023
 · 
8 min read
Drug Development
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
June 3, 2023
 · 
8 min read
Drug Development
Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting
June 3, 2023
 · 
11 min read
Drug Development
Intensity Therapeutics’ INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas - June 03, 2023
June 3, 2023
 · 
7 min read
Drug Development
Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
June 2, 2023
 · 
8 min read
Drug Development
Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session
June 2, 2023
 · 
3 min read
Drug Development
Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy Dose Escalation Results at ASCO 2023 Annual Meeting
June 2, 2023
 · 
3 min read
Drug Development
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
June 2, 2023
 · 
8 min read
Drug Development
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima
June 2, 2023
 · 
4 min read
Drug Development
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
June 1, 2023
 · 
9 min read
Drug Development
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment
June 1, 2023
 · 
1 min read
Drug Development
Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
June 1, 2023
 · 
4 min read
Drug Development
Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
June 1, 2023
 · 
5 min read
Drug Development
GenEros to Present Promising Results of GEC255 Phase I Clinical Trial for Advanced NSCLC Patients with KRAS G12C Mutation
June 1, 2023
 · 
3 min read
Drug Development
ReAlta Life Sciences Announces Proof of Mechanism Data from the Phase 1b Inhaled LPS Trial of RLS-0071, Demonstrating Powerful Inhibition of Lung Neutrophils and Inflammatory Cytokines
June 1, 2023
 · 
3 min read
Business
Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors
June 1, 2023
 · 
3 min read
Drug Development
Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody Therapy
June 1, 2023
 · 
2 min read
Drug Development
NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104
June 1, 2023
 · 
2 min read
Drug Development
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors
June 1, 2023
 · 
6 min read
Load More